This article was downloaded by: On: *27 January 2011* Access details: *Access Details: Free Access* Publisher *Taylor & Francis* Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t902189982

THREE NEW PRODUCTS FROM METHYL 3,4-DIPHENYL-5-NITRO-2-FUROATE BY CATALYTIC REDDCTION

K. Yamamoto^a; A. Tanaka^a; M. Ichikawa^b; S. Swaminathan^c; G. T. Bryan^c ^a Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama, JAPAN ^b Department of Pharmacy, School of Medicine, Nagasaki University, Nagasaki, JAPAN ^c Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison, WI

To cite this Article Yamamoto, K., Tanaka, A., Ichikawa, M., Swaminathan, S. and Bryan, G. T.(1987) 'THREE NEW PRODUCTS FROM METHYL 3,4-DIPHENYL-5-NITRO-2-FUROATE BY CATALYTIC REDDCTION', Organic Preparations and Procedures International, 19: 2, 255 – 257 **To link to this Article: DOI:** 10.1080/00304948709356193 **URL:** http://dx.doi.org/10.1080/00304948709356193

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

- F. W. Muellner, A. N. Abdel-Sayed, and L. Bauer, ibid., <u>22</u>, 1055 (1985).
- M. Kuzuya, A. Noguchi, S. Kamiya, and T. Okuda, Chem. Pharm. Bull. Japan, 33, 2313 (1985).
- (a) A. Bax, and R. Freeman, J. Magn. Reson., <u>42</u>, 164 (1981).
 (b) ibid., <u>44</u>, 542 (1981).
- Similar "through-space" coupling has been reported for some substituted anisoles, see, T. Schaefer, T. A. Wildman, and J. Peeling, J. Magn. Reson., 56, 144 (1984) and references quoted therein.

THREE NEW PRODUCTS FROM METHYL 3,4-DIPHENYL-5-

NITRO-2-FURGATE BY CATALYTIC REDUCTION

Submitted by K. Yamamoto*, A. Tanaka*, M. Ichikawa[†], S. Swaminathan^{††}, (08/29/86) and G. T. Bryan^{††}

- *Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-02, JAPAN
- † Department of Pharmacy, School of Medicine, Nagasaki University, 7-1 Sakamoto Machi, Nagasaki 852, JAPAN
- ++ Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 600 Highland Avenue, Madison, WI 53792

All biological effects of 5-nitrofurans^{1,2} seem to require the reduction of the 5-nitro group to a metabolically reactive intermediate.³ In the case of the carcinogenic 5-nitrofurylthiazoles, the postulated reduction products 5-nitroso and 5-hydroxylamino derivatives have not been conclusively identified since authentic samples have not yet been synthesized, partly because of the extreme lability of these intermediates. Even the 2-aminofurans are generally unstable and undergo fission of the

OPPI BRIEFS

furan ring to generate the ketonitrile derivatives.^{3,4} Because phenyl groups at positions 3 and 4 could exert a stabilizing effect on the furan ring, we reduced methyl 3,4-diphenyl-5-nitro-2-furoate $(I)^5$ as a model com-



pound to generate these products. Three new stable products were identified as methyl 3,4-diphenyl-5-hydroxylamino-2-furoate (II), methyl 3,4-diphenyl-5-amino-2-furoate (III) and methyl 3,4-diphenyl-4-cyano-2butanoate (IV).

EXPERIMENTAL SECTION

Mps are uncorrected. IR spectra were recorded on a Nippon Bunko DS-701G Infrared Spectrophotometer and ¹H-NMR spectra were taken with JNM-C-60H in ca. 4% (w/v) CDC1₃ with TMS as an internal standard. MS spectra were taken using JEOL-JMS-01SG Spectrometer. Elemental analyses were performed at Josai University.

Catalytic Hydrogenation of Methyl 3,4-Diphenyl-5-nitro-2-furoate (II).- A solution of I (10 g) in 400 ml of tetrahydrofuran (THF) was stirred with 5% Pd-C (3 g) over hydrogen at room temperature at atmospheric pressure, the absorption of hydrogen ceased after the calculated amount of hydrogen had been consumed. The catalyst was removed by filtration and the solvent removed <u>in vacuo</u>. The residue was dissolved in hot benzene (100 ml) and upon cooling, light yellow crystals deposited. Recrystallization from benzene yielded 6.2 g (65%) of II, mp. 178-180°. IR: 3300-3600 (NHOH), 1720 (C=0) cm⁻¹; ¹H-NMR (CDCl₃): δ 3.70 (3H, s, CH₃), 6.01 (1H, s, OH), 7.64 (10H, m, two phenyls), 8.25 (1H, br, NH); MS (m/Z): 309 (M⁺, 13%); 250 (100%); 204 (26%).

<u>Anal</u>. Calcd. for C₁₈H₁₅NO₄: C, 69.89; H, 4.89; N, 4.53

Found: C, 70.09; H, 4.71; N, 4.66

256

Volume 19, No. 2-3 (1987)

After separating II, the filtrate was concentrated and chromatographed on a silica gel column (100 g) and eluted with benzene. The first fraction (60 ml) was collected, concentrated, and recrystallized from benzene to yield 1.5 g (16%) of III as colorless plates, mp. 181-182°. IR: 3450 (NH₂), 1680 (C=0) cm⁻¹; ¹H-NMR (CDCl₃): δ 3.78 (3H, s, CH₃), 4.65 (2H, br, NH₂), 7.25 (10H, m, two phenyls); MS m/Z: 293 (M⁺, 100%); 235 (54%); 206 (25%). Anal. Calcd for C₁₈H₁₅NO₃: C, 73.70; H, 5.15; N, 4.78

Found: C, 73.82; H, 4.98; N, 4.67

The second fraction (100 ml) was collected (0.5 g, 5%) and recrystallized from benzene to give IV, mp. $126-127^{\circ}$. IR: 2220 (CN), 1760, 1728 (C=0) cm⁻¹; ¹H-NMR (CDCl₃): & 3.67 (3H, s, CH₃), 4.58 (1H, d, J=4.5 Hz, -CH-CH-), 5.00 (1H, d, J=4.5 Hz, -CH-CH-), 7.34 (10H, m, two phenyls); MS m/Z: 293 (M⁺, 100%); 235 (40%); 234 (51%); 206 (93%); 179 (58%); 178 (57.0%). <u>Anal</u>. Calcd. for C₁₈H₁₅NO₃: C, 73.70; H, 5.15; N, 4.78

Found: C, 73.62; H, 4.99; N, 4.91

Acknowledgements.- This work was supported in part by Grants CA 14520, and CA 14524 through the National Bladder Cancer Project, from the National Cancer Institute, NIH and by NIEHS Grant ES 03509. We thank Ms. S. Pertzborn and Ms. K. Blomstrom for editorial assistance with the manuscript preparation.

REFERENCES

- 1. G. T. Bryan, in G. T. Bryan, Ed., "Carcinogenesis. A Comprehensive Survey, Nitrofurans', Vol. 4, p. 1, Raven Press, New York, 1978.
- J. M. Klemencic and C. Y. Wang, ibid., p. 99; S. M. Cohen, ibid., p. 171.
- S. Swaminathan and G. M. Lower, Jr., ibid., p. 59, S. Swaminathan, G. M. Lower, Jr. and G. T. Bryan, Biochem. Pharmacol. 29, 3285 (1980); M. Ichikawa, K. Yamamoto, A. Tanaka, S. Swaminathan, J. F. Hatcher, E. Ertürk and G. T. Bryan, Carcinogenesis 7, 1339 (1986).
- A. H. Beckett and A. E. Robinson, J. Mednl. Pharm.. Chem. <u>1</u>, 135 (1959).
- 5. S. Yoshina, Japan Pat., 7,391,058 (1973) [C. A., 81, 77797 (1974)].

257